This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Explore the debate of cash back vs. points to determine which rewards suit your spending habits best. Make informed choices for your finances.
26,869 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
General Dynamics posted a strong first quarter, while Lockheed Martin unveiled a major Ultra Maritime purchase, sharp...
Deregulation can tilt the odds for certain industries and investment themes. This guide explains how to spot opportun...
Two midstream ETFs compete on tax structure and cash-flow strategy. A closer look at AMLP and MLPX reveals how holdin...
As lawmakers wrangle over the CLARITY Act, one name stands out for cautious investors: Bitcoin. This guide explains w...
Kraken has introduced regulated crypto spot margin trading in the United States, leveraging Bitnomial licenses acquir...
"forget magnificent seven. this" is a line gaining traction as an equal-weight S&P 500 fund outperforms the cap-weigh...
As the AI boom strong powers data-center growth, memory stocks are slipping. Analysts point to cyclical supply dynami...
As Treace Medical eyes 2026, investors weigh adoption of Lapiplasty, payer dynamics, and global expansion. This guide...
When a company executive moves tens of thousands of shares, it sparks questions. This guide explains what insider sel...
What happens when a director chooses a real puppet over CGI? This finance-focused look at practical effects translate...
Micron just posted standout results, fueling chatter about a potential stock split. This guide breaks down what a spl...